Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts

Magnetic Resonance Imaging

Volumn 21, Issue 5, 2003, Pages 475-482

  Checkley, David ^a   Tessier, Jean J L ^a   Wedge, Stephen R ^a   Dukes, Michael ^a   Kendrew, Jane ^a   Curry, Brenda ^a   Middleton, Brian ^a   Waterton, John C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Dynamic MRI; Ktrans; VEGF signaling; ZD4190

Indexed keywords

N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER GRAFT; CANCER INHIBITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; HISTOGRAM; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

MUS MUSCULUS;

EID: 0042307678     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0730-725X(02)00644-6     Document Type: Article

References (32)

1. Folkman J. Angiogenesis research: from laboratory to clinic. Forum Genova 1999;9:59-62.
2. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-43.
3. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-31.
4. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
5. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha HJ, Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. Embo J 1999;18:363-74.
6. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
7. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
8. Cross MJ, Claesson-Welsh LF. GF and VEGF function in angiogenesis: signalling pathways, biological responses, and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7.
9. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;60:970-5.
10. Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 2001;3:131-40.
11. Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 2000;6:4697-704.
12. Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, Essig M, Vaupel P, van Kaick G. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997;57:4777-86.
13. Eskey CJ, Koretsky AP, Domach MM, Jain RK. 2H-nuclear magnetic resonance imaging of tumor blood flow: spatial, and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res 1992;52:6010-9.
14. Zhu XP, Li KL, Kamaly-Asl ID, Checkley DR, Tessier JJ, Waterton JC, Jackson A. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575-85.
15. Furman-Haran E, Grobgeld D, Degani H. Dynamic contrast-enhanced imaging and analysis at high spatial resolution of MCF7 human breast tumors. J Magn Reson Imaging 1997;128:161-71.
16. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, Cohen RL, Brasch RC. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-30.
17. Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE, Leach MO. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997;7:564-74.
18. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33:564-8.
19. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997;3:780-2.
20. Furman-Haran E, Margalit R, Grobgeld D, Degani H. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc Natl Acad Sci USA 1996;93:6247-51.
21. Brasch R, Turetschek K. MRI characterization of tumors, and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000;34:148-55.
22. Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland MF, Roberts TP, Ferrara N, Jaffe RB, Brasch RC. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000;183:956-63.
23. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
24. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-67.
25. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990;16:117-31.
26. Harkness JE, Wagner JE. The biology and medicine of rabbits and rodents. Williams and Wilkins, 1995.
27. Siegel S, Castellan NJ. Nonparametric statistics for behavioural sciences. McGraw-Hill, 1988.
28. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin (C) + paclitaxel (T) + rhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Assoc Cancer Res 2001;12:1256 (Abstract).
29. Jayson GC, Mulatero C, Ranson M, Zweit J, Hastings D, Julyan P, Lawrance J, McGown A, Jackson A, Haroon H, Hakannson L, Wagstaff J, Groenewegen G, Lehmann F, Levitt D, Tang T, Zweirzina H. Anti-VEGF antibody HuMV833: an EORTC biological treatment development group phase I toxicity, pharmacokinetic, and pharmacodynamic study. Proc Am Assoc Cancer Res 2001;12:14 (Abstract).
30. Basser R, Hurwitz H, Barge A, Davis I, DeBoer R, Holden S, McArthur G, McKinley M, Nairn K, Persky M, Rischin D, Rosenthal M, Swaisland H, Eckhardt G. Phase 1 pharmacokinetic, and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors. Proc Am Assoc Cancer Res 2001;12:396 (Abstract).
31. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
32. Thompson WD, Shiach KJ, Fraser RA, McIntosh LC, Simpson JG. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth. J Pathol 1987;151(4):323-32.